Announcements
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
- Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
- Editas Medicine Announces Third Quarter 2023 Results and Business Updates
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.88 |
---|---|
High | 4.88 |
Low | 4.88 |
Bid | 4.93 |
Offer | 5.01 |
Previous close | 4.88 |
Average volume | 703.10 |
---|---|
Shares outstanding | 82.23m |
Free float | 81.97m |
P/E (TTM) | -- |
Market cap | 437.49m USD |
EPS (TTM) | -2.06 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:03 BST.
More ▼